Biology,
Год журнала:
2025,
Номер
14(3), С. 251 - 251
Опубликована: Фев. 28, 2025
CRC
remains
a
significant
public
health
challenge
due
to
its
high
prevalence
and
mortality
rates.
Emerging
evidence
highlights
the
critical
role
of
gut
microbiota
in
both
pathogenesis
efficacy
treatment
strategies,
including
chemotherapy
immunotherapy.
Dysbiosis,
characterized
by
imbalances
microbial
communities,
has
been
implicated
progression
therapeutic
outcomes.
This
review
examines
intricate
relationship
between
composition
CRC,
emphasizing
potential
for
profiles
serve
as
biomarkers
early
detection
prognosis.
Various
interventions,
such
prebiotics,
probiotics,
postbiotics,
fecal
transplantation,
dietary
modifications,
aim
restore
balance
shift
dysbiosis
toward
eubiosis,
thereby
improving
Additionally,
integration
profiling
into
clinical
practice
could
enhance
diagnostic
capabilities
personalize
advancing
field
oncology.
The
study
intratumoral
offers
new
prognostic
tools
that,
combined
with
artificial
intelligence
algorithms,
predict
responses
assess
risk
adverse
effects.
Given
growing
understanding
microbiome–cancer
axis,
developing
microbiota-oriented
strategies
prevention
holds
promise
patient
care
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(21), С. 6578 - 6578
Опубликована: Ноя. 1, 2024
Colorectal
cancer
(CRC)
constitutes
a
significant
global
health
challenge,
with
recent
studies
underscoring
the
pivotal
role
of
gut
microbiome
in
its
pathogenesis
and
progression.
Fecal
microbiota
transplantation
(FMT)
has
emerged
as
compelling
therapeutic
approach,
offering
potential
to
modulate
microbial
composition
optimize
treatment
outcomes.
Research
suggests
that
specific
bacterial
strains
are
closely
linked
CRC,
influencing
both
clinical
management
interventions.
Moreover,
microbiome's
impact
on
immunotherapy
responsiveness
heralds
new
avenues
for
personalized
medicine.
Despite
promise
FMT,
safety
concerns,
particularly
immunocompromised
individuals,
remain
critical
issue.
Clinical
outcomes
vary
widely,
influenced
by
genetic
predispositions
methodologies
employed.
Additionally,
rigorous
donor
selection
screening
protocols
paramount
minimize
risks
maximize
efficacy.
The
current
body
literature
advocates
establishment
standardized
further
trials
substantiate
FMT's
CRC
management.
As
our
understanding
deepens,
FMT
is
poised
become
cornerstone
treatment,
imperative
continued
research
validation.
Journal of Clinical Medicine,
Год журнала:
2023,
Номер
12(4), С. 1683 - 1683
Опубликована: Фев. 20, 2023
A
growing
body
of
evidence
suggested
that
gut
microbiota
is
associated
with
liver
diseases
through
the
gut–liver
axis.
The
imbalance
could
be
correlated
occurrence,
development,
and
prognosis
a
series
diseases,
including
alcoholic
disease
(ALD),
non-alcoholic
fatty
(NAFLD),
viral
hepatitis,
cirrhosis,
primary
sclerosing
cholangitis
(PSC),
hepatocellular
carcinoma
(HCC).
Fecal
transplantation
(FMT)
seems
to
method
normalize
patient’s
microbiota.
This
has
been
traced
back
4th
century.
In
recent
decade,
FMT
highly
regarded
in
several
clinical
trials.
As
novel
approach
reconstruct
intestinal
microecological
balance,
used
treat
chronic
diseases.
Therefore,
this
review,
role
treatment
was
summarized.
addition,
relationship
between
explored
axis,
definition,
objectives,
advantages,
procedures
were
described.
Finally,
value
therapy
transplant
(LT)
recipients
briefly
discussed.
Abstract
Fecal
microbiota
transplantation
(FMT)
has
emerged
as
a
promising
therapeutic
approach
for
dysbiosis‐related
diseases.
However,
the
clinical
practice
of
crude
fecal
transplants
presents
limitations
in
terms
acceptability
and
reproductivity.
Consequently,
two
alternative
solutions
to
FMT
are
developed:
transplanting
bacteria
communities
or
virome.
Advanced
methods
mainly
include
washed
spores
treatment.
Transplanting
virome
is
also
explored,
with
development
transplantation,
which
involves
filtering
from
feces.
These
approaches
provide
more
palatable
options
patients
healthcare
providers
while
minimizing
research
heterogeneity.
In
general,
evolution
next
generation
global
trends
components
focuses
on
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(10), С. 5561 - 5561
Опубликована: Май 20, 2024
This
review
scrutinizes
the
intricate
interplay
between
microbiome
and
human
body,
exploring
its
multifaceted
dimensions
far-reaching
implications.
The
microbiome,
comprising
diverse
microbial
communities
inhabiting
various
anatomical
niches,
is
increasingly
recognized
as
a
critical
determinant
of
health
disease.
Through
an
extensive
examination
current
research,
this
elucidates
dynamic
interactions
host
physiology
across
multiple
organ
systems.
Key
topics
include
establishment
maintenance
microbiota
diversity,
influence
factors
on
composition,
bidirectional
communication
pathways
cells.
Furthermore,
we
delve
into
functional
implications
dysbiosis
in
disease
states,
emphasizing
role
shaping
immune
responses,
metabolic
processes,
neurological
functions.
Additionally,
discusses
emerging
therapeutic
strategies
aimed
at
modulating
to
restore
host–microbe
homeostasis
promote
health.
Microbiota
fecal
transplantation
represents
groundbreaking
approach
management
dysbiosis-related
diseases,
offering
promising
avenue
for
restoring
balance
within
gut
ecosystem.
innovative
therapy
involves
transfer
from
healthy
donor
individual
suffering
dysbiosis,
aiming
replenish
beneficial
populations
mitigate
pathological
imbalances.
By
synthesizing
findings
fields,
offers
valuable
insights
complex
relationship
highlighting
avenues
future
research
clinical
interventions.
Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(2), С. 325 - 325
Опубликована: Янв. 6, 2024
Myalgic
encephalomyelitis/chronic
fatigue
syndrome
(ME/CFS)
is
a
chronic,
debilitating,
and
multi-faceted
illness.
Heterogenous
onset
clinical
presentation
with
additional
comorbidities
make
it
difficult
to
diagnose,
characterize,
successfully
treat.
Current
treatment
guidelines
focus
on
symptom
management,
but
no
clear
target
or
causative
mechanism,
remission
rates
are
low,
fewer
than
5%
of
patients
return
their
pre-morbid
activity
levels.
Therefore,
there
an
urgent
need
undertake
robust
trials
identify
effective
treatments.
This
review
synthesizes
insights
from
exploring
pharmacological
interventions
dietary
supplements
targeting
immunological,
metabolic,
gastrointestinal,
neurological,
neuroendocrine
dysfunction
in
ME/CFS
which
require
further
exploration.
Additionally,
the
trialling
alternative
based
reported
efficacy
illnesses
overlapping
symptomology
also
discussed.
Finally,
we
provide
important
considerations
recommendations,
focusing
outcome
measures,
ensure
execution
future
high-quality
establish
evidence-based
that
needed
for
adoption
practice.
Current Oncology Reports,
Год журнала:
2024,
Номер
26(3), С. 292 - 298
Опубликована: Фев. 20, 2024
Abstract
Purpose
of
the
Review
Microbiome
research
has
provided
valuable
insights
into
associations
between
microbial
communities
and
bladder
cancer.
However,
this
field
faces
significant
challenges
that
hinder
interpretation,
generalization,
translation
findings
clinical
practice.
This
review
aims
to
elucidate
these
highlight
importance
addressing
them
for
advancement
microbiome
in
Recent
Findings
underscore
complexities
involved
research,
particularly
context
Challenges
include
low
biomass
urine
samples,
potential
contamination
issues
during
collection
processing,
variability
sequencing
methods
primer
selection,
difficulty
establishing
causality
microbiota
Studies
have
shown
impact
sample
storage
conditions
DNA
isolation
kits
on
analysis,
emphasizing
need
standardization.
Additionally,
variations
can
introduce
affect
results.
The
choice
16S
rRNA
gene
amplicon
or
shotgun
metagenomic
introduces
technical
challenges,
including
selection
read
length.
Establishing
cancer
requires
experimental
like
fecal
transplantation
human
microbiota-associated
murine
models,
which
face
their
own
set
challenges.
Translating
therapeutic
applications
is
hindered
by
methodological
variability,
incomplete
understanding
bioactive
molecules,
imperfect
animal
inherent
heterogeneity
among
individuals.
Summary
presents
stemming
from
conceptual
complexities.
Addressing
through
standardization,
improved
advanced
analytical
approaches
essential
advancing
our
microbiome’s
role
its
applications.
Achieving
goal
lead
patient
outcomes
novel
strategies
future.
International Journal of Molecular Sciences,
Год журнала:
2024,
Номер
25(13), С. 7175 - 7175
Опубликована: Июнь 29, 2024
Obesity
is
a
global
health
challenge
that
has
received
increasing
attention
in
contemporary
research.
The
gut
microbiota
been
implicated
the
development
of
obesity,
primarily
through
its
involvement
regulating
various
host
metabolic
processes.
Recent
research
suggests
epigenetic
modifications
may
serve
as
crucial
pathways
which
and
metabolites
contribute
to
pathogenesis
obesity
other
disorders.
Hence,
understanding
interplay
between
mechanisms
for
elucidating
impact
on
host.
This
review
focuses
relationship
with
several
obesity-related
pathogenic
mechanisms,
including
energy
dysregulation,
inflammation,
maternal
inheritance.
These
findings
could
novel
therapeutic
targets
probiotics,
prebiotics,
fecal
transplantation
tools
treating
disruptions.
It
also
aid
developing
strategies
modulate
microbiota,
thereby
characteristics
obesity.
